Although induced pluripotent stem (iPS) cells have significant implications for overcoming most of the ethical issues associated with embryonic stem (ES) cells, there are still several unresolved issues related to the use of iPS cells for clinical applications, such as teratoma formation. In this study, we were able to generate tissue-specific stem (induced tissue-specific stem; iTS) cells from the pancreas (iTS-P) or liver (iTS-L) by transient overexpression of reprogramming factors, combined with tissue-specific selection. The generation of iTS cells was easier than that of iPS cells. The iTS-P/iTS-L cells express genetic markers of endoderm and pancreatic/hepatic progenitors and were able to differentiate into insulin-producing cells/hepatocytes more efficiently than ES cells. 
Although induced pluripotent stem (iPS) cells have significant implications for overcoming most of the ethical issues associated with embryonic stem (ES) cells, there are still several unresolved issues related to the use of iPS cells for clinical applications, such as teratoma formation. In this study, we were able to generate tissue-specific stem (induced tissue-specific stem; iTS) cells from the pancreas (iTS-P) or liver (iTS-L) by transient overexpression of reprogramming factors, combined with tissue-specific selection. The generation of iTS cells was easier than that of iPS cells. The iTS-P/iTS-L cells express genetic markers of endoderm and pancreatic/hepatic progenitors and were able to differentiate into insulin-producing cells/hepatocytes more efficiently than ES cells. Subcutaneous transplantation of both types of iTS cells into immunodeficient mice resulted in no teratoma formation. The technology used for the transient overexpression of reprogramming factors and tissue-specific selection may be useful for the generation of other tissue-specific stem cells, and the generation of iTS cells could have important implications for the clinical application of stem cells. Embryonic stem (ES) cells are capable of unlimited proliferation in vitro, while maintaining their potential to differentiate into cells from the three embryonic germ layers. Induced pluripotent stem (iPS) cells are generated from adult fibroblasts or other somatic cells, and are similar to ES cells in their morphology, gene expression, epigenetic status and in vitro differentiation. Mouse iPS cells give rise to adult chimeras and show competence for germline transmission. [1] [2] [3] [4] [5] [6] [7] This technical breakthrough has significant implications for overcoming the ethical issues associated with ES cell derivation from embryos. The generation of mouse iPS cells without the genomic integration of exogenous reprogramming factors by the repeated transfection of plasmids expressing Oct3/4, Sox2 (sex-determining region Y-box2), Klf4 and c-Myc, 8 and by using nonintegrating adenoviruses transiently expressing the four factors 9 has been reported. Moreover, the generation of human iPS cells without the genomic integration of exogenous reprogramming factors by plasmids expressing Oct3/4, Sox2, Klf4, c-Myc, Nanog, LIN28 and SV40LT, 10 or Oct3/4, Sox2, Klf4, L-Myc, LIN28 and p53 shRNA 11 has been shown. These reports provide strong evidence that insertional mutagenesis is not required for in vitro reprogramming. The production of iPS cells without viral integration addresses a critical safety concern for the potential use of iPS cells in regenerative medicine. However, the use of iPS cells for clinical therapies is hampered by their potential for tumor formation and the limited ability to generate pure populations of differentiated cell types in vitro.
Adult tissue-specific stem/progenitor cells could represent one of the alternative sources for the treatment of diseases. Several in vitro studies have shown that insulin-producing cells (IPC) can be generated from adult pancreatic ductal tissues. [12] [13] [14] The assessment of 83 human islet grafts transplanted using the Edmonton Protocol since 1999 15 showed that a significant positive correlation was observed between the number of islet progenitor (ductal-epithelial) cells transplanted and the long-term metabolic success, as assessed by an intravenous glucose tolerance test at B2 years post-transplantation. Therefore, pancreatic duct/ progenitor cells could become a new source of IPC. One of the most difficult, and yet unresolved issues, is how to isolate pancreatic 'stem' cells, which have self-renewal capacity. We and other groups have established mouse pancreatic stem cell lines using specific culture conditions. 16, 17 One of our established pancreatic stem cell lines, HN#13, derived from the pancreatic tissue of an 8-week-old mouse without genetic manipulation could be maintained during repeated passages for more than 1 year without growth inhibition under specific culture conditions. The HN#13 cells do not have tumorigenic properties, and have normal chromosomes. The cells express the pancreatic and duodenal homeobox factor-1 (Pdx1), one of the transcription factors of the b-cell lineage. 17 However, we were unable to isolate and culture mouse pancreatic stem cells from older donors 18 or pancreatic stem cells from human pancreatic tissue. 19 In the mouse study, pancreatic stem cells were isolated from the pancreata of all newborn mice examined. Meanwhile, pancreatic stem cells were isolated from only 10% of the pancreata of 8-week-old mice, not from the pancreata of any 24-week-old mice. 18 These data suggest that young donors have a larger number of pancreatic stem cells, whereas that older donors have few or virtually no pancreatic stem cells. These data also indicate that it is extremely difficult to isolate pancreatic stem cells from older donors.
In this study, we were able to generate tissue-specific stem (induced tissue-specific stem; iTS) cells from mouse pancreatic tissue (iTS-P) by transient overexpression of reprogramming factors combined with Pdx1 selection. Furthermore, we were also able to generate iTS cells from the mouse liver (iTS-L) by transient overexpression of reprogramming factors combined with HNF4a selection.
Results

Generation of iTS-P cells from mouse pancreatic tissue.
We attempted to generate mouse iPS cells from older-donor pancreata by transfection of a single plasmid expressing Oct3/4, Sox2 and Klf4 with or without c-Myc. The three or four cDNAs were connected in this order with the 2A peptide and inserted into a plasmid containing the CMV or CAG 20 promoter (Supplementary Figure 1a) . We transfected the OSKM plasmid (four factors) or OKS plasmid (three factors) into pancreatic tissue obtained from 24-week-old mice on days 1, 3, 5 and 7 ( Figure 1a ). We were able to generate only one colony of iPS cells from 24-week-old mouse pancreata using the OSKM plasmid during five experiments and were unable to generate iPS cells using the OKS plasmid throughout five experiments. However, we noticed that there were some cells that had self-renewing potential. The morphology of some cells was similar to that of mouse pancreatic stem cells, which we had previously established from young-donor pancreata without genetic manipulation. 17 We designated them 'induced tissue-specific stem (iTS-P) cells'. Morphology of the other cells was similar to that of fibroblast cells, which we designated 'induced fibroblast-like (iF) cells' (Figure 1b) .
To evaluate the plasmid integration in these cells (passage 45), genomic DNA was amplified by polymerase chain reaction (PCR) with specific primers (Supplementary Figure 1a; Supplementary Table 1) . Although the PCR detected plasmid incorporation into the host genome of some cells, no amplification of plasmid DNA was observed in several cells, such as iTS-P 3F-1 and iTS-P 4F-1 (Supplementary Figures 1b  and c) . Although we cannot formally exclude the presence of small plasmid fragments, these data show that some of the cells that have self-renewal capacity are most likely free from plasmid integration into the host genome.
Generative efficacy and characterization of iTS-P cells.
To evaluate the efficiency of generating iTS-P cells, the OSKM plasmid or OKS plasmid were transfected into pancreatic tissue from five different mice that were 24 weeks old (one experiment using one mouse). A total of 14 colonies of iTS-P cells were generated using the OKS plasmid during five experiments, and a total of 41 colonies of iTS-P cells were generated using the OSKM plasmid during five experiments, thus suggesting that the OSKM plasmid induces iTS-P cells more efficiently than OKS plasmid. Moreover, the generation of iTS-P cells was easier than that of iPS cells (Figure 1c ). Mock transfection (no factors) did not yield any iTS-P or iF cells. There was plasmid integration in two clones of the 14 colonies generated using the OKS plasmid (14.3%) and in five clones of the 41 colonies generated using the OSKM plasmid (12.2%).
To investigate the gene expression in these cells, a reverse transcription PCR (RT-PCR) analysis of ES cell marker genes was performed. The high-level expression of the pluripotency markers Oct3/4, Sox2 and Nanog was limited to ES and iPS cells (Supplementary Figure 2) . We next investigated the gene expression patterns of endodermal/pancreatic progenitor (PP) cell markers. Differentiated cells from ES cells (generated by a stepwise differentiation protocol that relies on intermediates thought to be similar to the cell populations present in the developing embryo) 21, 22 were used as a positive control (Supplementary Figure 3a) . The expression of marker genes of the definitive endoderm (DE; Sox17), gut tube endoderm (GTE; hepatocyte nuclear factor 4a; Hnf4a) and PP (Pdx1) was detected in iTS-P cells, which was similar to the patterns detected in our mouse pancreatic stem cell line, HN#13, but not iF, iPS or ES cells ( Supplementary  Figures 3b-g ).
The iTS-P 3F-1/4F-1 cells continued to divide actively beyond passage 80 without changes in their morphology or growth activity (Figure 1d ). To examine the teratoma formation and tumorigenic potential in vivo, iTS-P 3F-1/4F-1 cells (10 6 -10 7 cells) at passage 45 were transplanted into nude or NOD/scid mice. No teratomas or tumors developed in the nude or NOD/scid mice that received iTS-P 3F-1/4F-1 Table 1 ). These data indicate that the iTS-P 3F/4F cells do not have the ability to form teratomas. Figure 5a) . To evaluate whether the differentiated cells had glucose sensitivity, the differentiated cells from the iTS-P 4F-1 clone were exposed to low (2.8 mM) or high (20 mM) concentrations of glucose. The cells released about sixfold higher amounts of mouse insulin than an ES-derived population at both glucose concentrations ( Figure 1g ). The stimulation index was similar between the differentiated cells from iTS-P 4F-1 cells and ES cells (Supplementary Figure 5b) .
Generation of iTS-P cells by the expression plasmid and Pdx1 selection. We next attempted to achieve the efficient selection of iTS-P cells, as there was a large number of iF cells also included in the above experiments. As iTS-P 4F-1 cells expressed the Pdx1 transcription factor at both the mRNA (Supplementary Figure 3g) and protein level (Figure 1e ), we used a plasmid containing a neomycin resistance (NeoR) gene that was driven by the Pdx1 promoter (Supplementary Figure 6a) . We transfected the OSKM plasmid and pPdx1-NeoR plasmid together into the pancreatic tissue obtained from a 24-week-old mouse on days 1, 3, 5 and 7 (Figure 2a) , and G418 was added to the ES culture media from day 10 to 15 to select Pdx1-expressing cells. We obtained multiple colonies (iTS-P 4FP-1 to -6; Figure 2b ) that had self-renewal capacity and were morphologically similar to iTS-P 4F-1 cells. There were no fibroblast-like colonies in this experiment. To evaluate the plasmid integration in these cells (passage 45), genomic DNA from these cells was amplified by PCR with the primers indicated in Supplementary Figure 1a . Although PCR detected plasmid incorporation into the host genome of some cells, no amplification of plasmid DNA was observed in iTS-P 4FP-1, -2, -4 or -6 cells (Supplementary Figure 6b) .
Generative efficacy and characterization of iTS-P 4FP cells. To evaluate the efficiency of generating iTS-P 4FP cells, the OSKM plasmid and pPdx1-NeoR plasmid were transfected into pancreatic tissue from five different mice that were 24 weeks old (one experiment using one mouse). A total of 20 colonies of iTS-P cells were generated using the OSKM plasmid and pPdx1-NeoR plasmid during five experiments ( Figure 2c ). As a total of 41 colonies of iTS-P 4F cells were generated using only the OSKM plasmid during five experiments, the efficiency of iTS-P cell generation decreased when the pPdx1-NeoR was also used. This may have been due to the relatively lower concentration of OSKM plasmid per cell due to the addition of pPdx1-NeoR. There was plasmid integration in three clones of the 20 colonies generated (15.0%).
To investigate the gene expression profile in these cells, a RT-PCR analysis of ES cell marker genes, endodermal marker genes and pancreatic marker genes was performed (Figures 2d, e and 3) . No teratomas or tumors developed in the NOD/scid mice receiving iTS-P 4FP-1, -2, -4 and -6 cells (Table 1 ). These data indicate that the iTS-P 4FP cells express endodermal markers, and do not form teratomas.
Differentiation of iTS-P 4FP cells into IPC. To determine whether they could differentiate into IPC, we applied the stage 4-5 protocol from the stepwise differentiation protocol (shown in Supplementary Figure 3a) to the iTS-P 4FP cells. All of the iTS-P 4FP clones without plasmid integration were differentiated into IPC by the stage 4-5 protocol (Figure 2f;   Supplementary Figure 7) . 20.0 ± 1.4% of the differentiated cells were insulin/C-peptide positive on immunostaining and expressed endocrine-specific gene products (Supplementary Figure 8) . All of the differentiated cells from iTS-P 4FP-1, -2, -4 and -6 cells released mouse insulin on exposure to both the low and high concentrations of glucose (Figure 2g) , although the amount of insulin produced differed among the cells. The stimulation index was also different among the clones. These data suggest that the pPdx1-NeoR plasmid can efficiently select iTS-P cells, but the differentiation ability of the cells into IPC depends on the individual clone. 
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Hnf4α Hnf6 (Figure 4b) . A total of 58 colonies of iTS-L cells were generated during five experiments (one experiment using one mouse), thus suggesting that the generation of iTS-L cells is easier than that of iPS cells (Figures 4c and d) .
We evaluated the plasmid integration in these cells (passage 45). No amplification of plasmid DNA was observed in several cells, such as iTS-L 4F-1 ( Supplementary  Figure 9a) . There was plasmid integration into seven clones of 58 colonies generated using the OSKM plasmid (12.1%). Table 1 ).
Characterization of iTS-L cells. To investigate the gene expression in these cells, an RT-PCR analysis of ES
Differentiation of iTS-L cells into hepatocytes.
To determine whether iTS-L cells can be differentiated into hepatocytes, we applied the differentiation protocol reported previously. 23 The iTS-L cells were successfully differentiated into albumin-producing cells (Figure 4g) . A quantitative RT-PCR analysis confirmed the expression of hepatocytespecific gene products, such as a1-antitrypsin (a1-AT), glucose 6-phosphatase (G6PC) and albumin. The iTS-L 4F-1 cells were differentiated into hepatocytes more efficiently than ES cells or iPS cells derived from liver cells (Figures 5a and b; Supplementary Figure 10c ). Other clones (iTS-L 4F-2 and iTS-L 4F-3) were also differentiated into hepatocyte (Supplementary Figure 10d) , although the level of albumin mRNA differed among the cells. These data suggest that iTS-L cells can be differentiated into hepatocytes, but the differentiation ability depends on the individual clone.
Restriction of iTS cell developmental potential. To determine whether the developmental potential of iTS-P/ iTS-L cells was restricted to pancreas/liver lineages, respectively, cultures were induced using the conditions established to drive ES cells toward hepatocytes, IPC, neuroectoderm 24 or mesoderm. 23 The upregulation of albumin mRNA was limited to iTS-L cells (Figure 5b ) and the upregulation of insulin mRNA was limited to iTS-P cells (Figure 5c ). Moreover, the upregulation of the mesoderm markers platelet/ endothelial cell adhesion molecule 1 (Pecam1) or Mix1 homeobox-like 1 (Mixl1; Figure 5d ), and neuroectoderm markers zinc finger protein of the cerebellum 1 (Zic1) or Sox1 (Figure 5e ), was not observed in either the iTS-P or iTS-L cells, thus suggesting that iTS cells are committed to a specific type of tissue development.
Discussion
The iPS technology has significant implications for overcoming most of the ethical issues associated with ES cell derivation from embryos. However, the iPS cells still have some ethical issues, because they have similar or the same potency as ES cells, such as issues posed by human cloning. When we focus on the treatment of patients, differentiated tissue is needed. Although islet/liver transplantation is an efficient strategy for the treatment of diabetes/liver failure, 25 it is circumscribed by the limited and irregular supply of cadaveric donors and the risks of immunosuppressant therapy. In this study, we induced pancreatic/liver stem cells from mouse pancreatic tissue/liver cells by transient overexpression of reprogramming factors and tissue-specific selection. The iTS-P/iTS-L cells were able to differentiate into IPC/hepatocytes more efficiently than ES cells. On the other hand, the iTS-P/iTS-L cells did not differentiate into mesoderm or neuroectoderm. As the iTS-P/iTS-L cells are pancreas/liver-specific stem cells, the use of these cells seems to have fewer ethical concerns than ES cells and even iPS cells, because there are no concerns regarding their potential use to generate germ cells, and no need to destroy an embryo. Moreover, the iTS-P/iTS-L cells do not form teratomas. The ES/iPS cells have a risk for teratoma formation, even after transplantation of differentiated cells derived from ES/iPS cells, due to possible contamination with undifferentiated cells. This is one of the advantages of iTS-P/ iTS-L cells compared with ES/iPS cells in terms of their potential clinical use. On the other hand, we performed transplantation of undifferentiated iTS-P cells in normal nude mice and nude mice with diabetes; however, there were few/ no IPC in the grafts. We also performed transplantation of undifferentiated iTS-L cells in normal nude mice and nude mice with liver failure (90% hepatectomy); however, there were few/no albumin-producing cells in the grafts. These data suggest that undifferentiated iTS cells themselves cannot be used to treat the disease and that establishing differentiational protocols are important for clinical application.
Our control study using a plasmid with no factors showed no existing adult pancreatic stem cell population in the 24-weekold mice (Figure 1c) . Therefore, iTS-P cells were definitively induced by three or four factors. It has recently been shown that, following the reprogramming of mouse/human iPS cells, an epigenetic memory is inherited from the parental cells. [26] [27] [28] [29] [30] It was also shown that the epigenetic memory predisposes iPS cells derived from pancreatic b cells to differentiate more readily into IPC. 31 These findings demonstrate that the iPS cell phenotype may be influenced by their cells of origin, and suggest that their skewed differentiation potential may prove useful in the generation of differentiated cell types that are currently hard to produce from ES/iPS cells for the treatment of human diseases. The iTS-P/iTS-L cells have to be cells that inherit numerous components of epigenetic memory from Some groups have shown that overexpression of Pdx1, Ngn3, NeuroD and/or MafA by adenoviruses in vivo directly converted liver cells [32] [33] [34] or pancreatic tissue 35 into IPC, suggesting that direct reprogramming without reversion to a pluripotent stem cell state is possible. These reports of direct reprogramming without reversion to a pluripotent stem cell state seem to have fewer related ethical issues than iPS cells. However, these strategies require a large number of mature cells, and the induction therapy has to be done on all of these cells directly, because they are not stem cells and do not have self-renewal capacity. Two major advantages of iPS/iTS cells are that they can be generated from a small number of cells, and they will expand to a sufficient number of cells because they have self-renewal capacity.
In this study, we used crude material instead of defined pancreatic populations. Our recent study showed that iTS-P cells can be generated from both islet and non-islet cell populations. Moreover, we recently established iTS-P cells using the pancreatic tissue of NOD mice, suggesting that iTS-P cells can be generated from pancreatic cells derived from patients with type 1 diabetes.
In conclusion, we generated iTS cells from mouse pancreas/liver cells by transient overexpression of reprogramming factors and tissue-specific selection. The generation of iTS-P/iTS-L cells and their differentiation into IPC/ hepatocytes have important implications due to their potential use for autologous cell replacement therapy, and because they appear to be more easily and efficiently differentiated than ES cells. The technology to generate iTS cells by reprogramming factors and tissue-specific selection may also be useful for the generation of other tissue-specific stem cells.
Materials and Methods
Mice and cell culture. All mouse studies were approved by the review committee of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Chiba-East National Hospital, National Hospital Organization. The 24-week-old C57/BL6 mice (CREA) were used for primary pancreatic/liver tissue preparations. Each mouse pancreas/liver was digested with 2 ml cold M199 medium containing 2 mg/ml collagenase (Roche Diagnostics Corporation, Indianapolis, IN, USA). The digested tissues were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Carlsbad, CA, USA) with 10-20% fetal bovine serum (FBS; BIO-WEST, Inc., Logan, UT, USA). The 8-week-old nude or NOD/scid mice (CREA) were used for teratoma formation studies.
Mouse ES cells (ATCC, Manassas, VA, USA), iPS cells and iTS cells were maintained in complete ES cell media w/15% FBS (Millipore, Billerica, MA, USA) on feeder layers of mitomycin C-treated STO or SNB cells, as described previously. 1, 36 ES cells were passaged every 3 days, and iTS cells were passaged every 5 days.
Plasmid construction and transfection. To generate the OSKM plasmid, the cDNAs encoding Oct3/4, Sox2, Klf4 and c-Myc were connected in this order with the 2A peptide and inserted into a plasmid containing the CMV promoter. The OKS (Addgene, Cambridge, MA, USA: Plasmid 19771 (pCX-OKS-2A)) or OSKM plasmid was transfected into pancreas/liver cells from 24-week-old mice on days 1, 3, 5 and 7, as previously described. 8 Colonies were manually picked at 30-45 days after first transfection. To attempt efficient selection of iTS-P cells, we used a plasmid containing a NeoR gene that was driven by the Pdx1 promoter (pPdx1). To generate the pPdx1-NeoR plasmid, the Cre gene in the Pdx1-Cre plasmid (Addgene: Plasmid 15021 (DM#258); https://www.addgene.org/ 15021/) was replaced with the NeoR gene, derived from pIRES-neo (Clontech, Mountain View, CA, USA). The detail protocol is shown in Supplementary Information.
DNA purification and PCR. DNA was extracted from cells using the AllPrep DNA/RNA Mini Kit (Qiagen, Tokyo, Japan). Polymerization reactions were performed in a Perkin-Elmer 9700 Thermocycler with 3 ml cDNA (20 ng DNA equivalents), 160 mmol/l cold dNTPs, 10 pmol appropriate oligonucleotide primers, 1.5 mmol/l MgCl 2 and 5 U AmpliTaq Gold DNA polymerase (Perkin-Elmer, Norwalk, CT, USA) in 1 Â PCR buffer. The oligonucleotide primers are shown in Supplementary Table 1. The thermal cycle profile used a 10-min denaturing step at Quantification of the mRNA levels was carried out using the TaqMan real-time PCR system, according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). PCR was performed for 40 cycles, including 2 min at 50 1C and 10 min at 95 1C as initial steps. In each cycle, denaturation was performed for 15 s at 95 1C and annealing/extension was performed for 1 min at 60 1C. PCR was carried out in 20 ml of solution using cDNAs synthesized from 1.11 ng of total RNA. For each sample, the expression of mRNA was normalized by dividing the b-actin expression level. Primers for mouse insulin-1, insulin-2, a1-AT, G6PC, albumin, Pecam1, Mixl1, Zic1, Sox1, Oct3/4, Sox2, Nanog, Sox17, Hnf4a, Pdx1 and b-actin are commercially available (Assays-on-Demand Gene Expression Products; Applied Biosystems).
Cell induction and differentiation. Directed differentiation into IPC was conducted as described previously, 21, 22 with minor modifications. ES cells, iPS cells (passage 45), iTS-P cells (passage 45 and 80) were used in this experiment. In stage 1, cells were treated with 25 ng/ml of Wnt3a and 100 ng/ml of activin A (R&D Systems, Minneapolis, MN, USA) in RPMI (Life Technologies) for 1 day, followed by treatment with 100 ng/ml of activin A in RPMI þ 0.2% FBS for 2 days. In stage 2, the cells were treated with 50 ng/ml of FGF10 (R&D Systems) and 0.25 mM of KAAD-cyclopamine (Toronto Research Chemicals, Toronto, ON, Canada) in RPMI þ 2% FBS for 3 days. In stage 3, the cells were treated with 50 ng/ml of FGF10, 0.25 mM of KAAD-cyclopamine and 2 mM of all-trans retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) in DMEM þ 1% (vol/vol) B27 supplement (Life Technologies) for 3 days. In stage 4, the cells were treated with 1 mM of DAPT (Sigma-Aldrich) and 50 ng/ml of exendin-4 (Sigma-Aldrich) in DMEM þ 1% (vol/vol) B27 supplement for 3 days. In stage 5, the cells were then treated with 50 ng/ml of exendin-4, 50 ng/ml of IGF-1 (Sigma-Aldrich) and 50 ng/ml of HGF (R&D Systems) in CMRL (Life Technologies) þ 1% (vol/vol) B27 supplement for 3-6 days. Differentiation into hepatocytes, neuroectoderm or mesoderm was conducted as reported previously. 23, 24 Teratoma formation/tumorigenicity assay. A total of 1 Â 10 6 -1 Â 10 7 of iPS/iTS cells were inoculated into one thigh each of nude or NOD/scid mice. As a positive control, we transplanted 1 Â 10 6 ES cells or iPS cells into the other thigh of the nude or NOD/scid mice.
Immunostaining. Cells were fixed with 4% paraformaldehyde in PBS buffer. After blocking with 20% AquaBlock (EastCoast Bio, North Berwick, ME, USA) for 30 min at room temperature, the cells were incubated overnight at 4 1C with a goat anti-insulin antibody (1 : 100; Abcam, Tokyo, Japan), rabbit anti-C-peptide antibody (1 : 100; Cell Signaling Technology, Danvers, MA, USA), rabbit anti-Pdx1 antiserum 37 (1 : 1000) or rabbit anti-albumin (Cedarline, Gymea, NSW, Australia) and then for 1 h at room temperature with FITC-conjugated anti-goat IgG 
